Novartis

Extracted Attributes

• Type

  Multinational pharmaceutical corporation

• Founded

  1996-03-01

• Industry

  Pharmaceuticals and Healthcare

• Employees

  78,000 (as of 2024)

• Headquarters

  Basel, Switzerland

• Key Products

  clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), terbinafine (Lamisil), deferasirox (Exjade), Entresto, Cosentyx, Kesimpta, Kisqali, Tasigna

• Founding Event

  Merger of Ciba-Geigy and Sandoz

• Revenue (2023)

  $51.7 billion

• Market Position

  One of the world's largest pharmaceutical companies, 8th largest by revenue in 2024, 3rd most valuable in Europe

• Patients Reached

  296 million worldwide

• Global Research Operations

  Cambridge, Massachusetts, United States

• Countries with Products Sold

  118

Timeline

• Formed through the merger of Ciba-Geigy and Sandoz, integrating their pharmaceutical and agrochemical divisions. (Source: Summary)

  1996-03-01

• Divested its agrochemical and genetically modified crops business by spinning off Syngenta in partnership with AstraZeneca. (Source: Summary)

  2000-01-01

• Revived the Sandoz brand to consolidate its generic drugs businesses. (Source: Summary)

  2003-01-01

• Sold its diclofenac (Voltaren) business to GlaxoSmithKline. (Source: DBpedia)

  2015-01-01

• Ceased production of methylphenidate (Ritalin). (Source: DBpedia)

  2020-01-01

Web Search Results

• Novartis AG Company Profile - GlobalData

  Novartis AG (Novartis) is a pharmaceutical company that is engaged in the research, development, manufacturing, distribution, marketing, and sale of innovative medicines. It offers a range of products in therapeutic areas such as cardiovascular, renal and metabolic, immunology, ophthalmology, respiratory, global health, neuroscience, and oncology. The company offers its products to pharmacists, private health systems, government agencies, physicians, hospitals, insurance groups, managed care [...] providers, pharmacy benefit managers, and government-supported healthcare systems through brands such as Entresto, Cosentyx, Kesimpta, Kisqali, and Tasigna, among others, globally. It operates manufacturing facilities in the US, Switzerland, Austria, Slovenia, China, France, and Italy. Novartis is headquartered in Basel, Switzerland. [...] Gain a 360-degree view of Novartis AG and make more informed decisions for your business Gain a 360-degree view of Novartis AG and make more informed decisions for your business Register your interest Headquarters Switzerland Address Lichtstrasse 35, Basel, Basel-Stadt, 4056 Website www.novartis.com Telephone 41 613 241111 No of Employees 75,883 Industry Pharmaceuticals and Healthcare Ticker Symbol & Exchange NOVN (SWF) Revenue (2023) $51.7B 10.8% (2023 vs 2022) EPS XYZ

• Novartis - Wikipedia

  Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group and owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group.( In the United States, they operate as Novartis Pharmaceuticals Corporation (NPC) headquartered in New Jersey. [...] ( Novartis AG is a Swiss multinationalpharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.( [...] Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA),( the Biotechnology Innovation Organization (BIO),( the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),( and the Pharmaceutical Research and Manufacturers of America (PhRMA).( Novartis is the third most valuable pharmaceutical company in Europe, after Novo Nordisk and Roche. History [edit]

• Company overview - Novartis

  Skip to main content Header # Company overview ## About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. ### Board of Directors [...] Novartis aims to hold itself to high standards of sustainability and ethical business practices. ### News archive Get the latest news and information from Novartis. ### Financial data Review and download annual and quarterly reports, SEC filings and product sales information. ## Reporting and transparency hub Read our regulatory filings; policies, codes and guidelines that govern our activities; and environmental, social and governance (ESG) disclosures. Learn more [...] When you visit any website, it may store or retrieve information on your browser by using cookies. The cookies are set to expire when the information is no longer needed or after a maximum period of 13 months. You can choose to allow or not to allow some specific types of cookies. Click on the different category headings below to find out more. Please note that blocking some types of cookies may impact your experience on the site and the services we are able to offer.

• Novartis News Via Stat: Latest on the Pharmaceutical Company

  Novartis is a pharmaceutical and biotechnology giant based in Basel, Switzerland and Cambridge, Mass. It has more than 100,000 employees and revenue in excess of $50 billion annually. Here’s a roundup of STAT coverage. Latest Image 3 The Readout Meghana Keshavan ### Image 4 STAT Plus: More beef in the gene editing space Image 5 Biotech Brittany Trang ### Image 6 STAT Plus: Novartis strikes AI drug development deal with Generate:Biomedicines Image 7 Health Angus Chen

• About | Novartis

  Skip to main content Header # About Learn more about Novartis and explore our core therapeutic areas and technology platforms. Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide. ## Our purpose ## Reimagine medicine to improve and extend people's lives. ## Our vision [...] ## Become the most valued and trusted medicines company in the world. ## Our strategy ## Deliver high value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. ## Our footprint 78k #### Employees 118 #### Countries with products sold 296m #### Patients reached Download the Novartis in Society Integrated Report 2024 for more details (PDF 5.0 MB)") [...] When you visit any website, it may store or retrieve information on your browser by using cookies. The cookies are set to expire when the information is no longer needed or after a maximum period of 13 months. You can choose to allow or not to allow some specific types of cookies. Click on the different category headings below to find out more. Please note that blocking some types of cookies may impact your experience on the site and the services we are able to offer.

• Award

  Public Eye Swiss Award

• Image

  

• Country

  Switzerland

• Employees

  119,418

• Instance Of

  Q161726

• Headquarters

  Basel

• Inception Date

  1/1/1996

Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland andCambridge, Massachusetts, United States (global research). It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine (Lamisil), deferasirox (Exjade), and others. In March 1996, the companies Ciba-Geigy and Sandoz merged to form Novartis; the pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. Other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).